
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx is off to a strong start in 2026 with Q1 revenue growth and GM both ahead of the company's guidance for the year. Its proprietary Barostim technology and the expansion of its TAM through the BENEFIT-HF trial could potentially lead to increased sales and revenue in the future. However, CVRx's heavy reliance on a single product and market, as well as the need for continued physician and patient marketing and adequate reimbursement, present potential risks.
Bears say
CVRx is a medical device company with a proprietary platform technology, Barostim, that addresses cardiovascular diseases by leveraging the power of the brain. Despite optimism around the company's growth, its current revenue is still primarily derived from the US market and is heavily reliant on sales productivity and steady adoption of Barostim therapy. Additionally, while the recent Category I CPT code and increased facility with Innovatus Capital Partners provide some financial stability in the short term, there are still potential risks of dilution and challenges with payer approvals that could impact future growth.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares